Nucleic acid molecules and polypeptides encoding baboon TAFI

Details Nucleic acid molecules and polypeptides encoding baboon TAFI Nucleic acid molecules and polypeptides encoding baboon TAFI

2006-08-15

2006-08-15

Weber, Jon (Department: 1653)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C530S350000, C530S395000

Reexamination Certificate

active

07091331

ABSTRACT:
The present invention relates to the isolation and identification of novel baboon nucleic acid molecules and proteins and polypeptides encoded by such nucleic acid molecules, or degenerate variants thereof, which proteins and polypeptides comprise novel baboon thrombin-activatable fibrinolysis inhibitors or “TAFI” enzyme molecules. Because the novel baboon TAFI proteins and polypeptides of the invention inhibit the breakdown of blood clots, they may be therapeutically useful for the treatment of blood disorders wherein clotting needs to be regulated or promoted, such as hemophilia or von Willebrand's disease or in other situations, such as trauma, wherein blood clotting or coagulation needs to be regulated or promoted. The sequences of the invention are also useful in screening methods for the identification of compounds that modulate the expression of the baboon TAFI nucleic acids and/or the activity of the baboon TAFI proteins and polypeptides of the invention. Such agonist or antagonist compounds may be useful in the treatment of various blood clotting disorders and conditions requiring hemostatic control such as hemophilia or various thrombotic diseases such as deep venous thrombosis, coronary artery disease, stroke associated with atrial fibrillation and recurrent thrombosis following stroke or myocardial infarction.

REFERENCES:
patent: 5010175 (1991-04-01), Rutter et al.
patent: 5206161 (1993-04-01), Drayna et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5364934 (1994-11-01), Drayna et al.
patent: 5474901 (1995-12-01), Drayna et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5519134 (1996-05-01), Acevedo et al.
patent: 5525735 (1996-06-01), Gallop et al.
patent: 5539083 (1996-07-01), Cook et al.
patent: 5549974 (1996-08-01), Holmes
patent: 5569588 (1996-10-01), Ashby et al.
patent: 5593674 (1997-01-01), Drayna et al.
patent: 5593853 (1997-01-01), Chen et al.
patent: 5985562 (1999-11-01), Morser et al.
patent: 6020141 (2000-02-01), Pantoliano et al.
patent: 6036920 (2000-03-01), Pantoliano et al.
patent: 6455294 (2002-09-01), Gan et al.
patent: 6818429 (2004-11-01), Gan et al.
patent: 2003/0017574 (2003-01-01), Gan et al.
patent: 2004/0006205 (2004-01-01), Li et al.
patent: 2005/0042670 (2005-02-01), Gan et al.
patent: 1 531 333 (2003-11-01), None
patent: WO 91/19735 (1991-12-01), None
patent: WO 92/00091 (1992-01-01), None
patent: WO 93/20242 (1993-10-01), None
patent: WO 98/55645 (1998-12-01), None
patent: WO 00/55180 (2000-09-01), None
patent: WO 00/66717 (2000-11-01), None
patent: WO03/014391 (2002-02-01), None
patent: WO 02/083841 (2002-10-01), None
patent: WO 04/020587 (2004-03-01), None
patent: WO 04/083403 (2004-09-01), None
NCBI Entrez Accession No. gi|231202, Rees, D.C. et al., Oct. 7, 1998.
NCBI Entrez Accession No. gi|21465928, Barbosa Pereira, P.J. et al., Jan. 30, 2002.
NCBI Entrez Accession No. gi:4503005, Zhao, L. et al., Dec. 20, 2003.
Morange, et al., “Ala147Thr and C+1542G Polymorphisms in the TAFI Gene Are Not Associated With A Higher Risk Of Venous Thrombosis In FV Leiden Carriers”, Thromb Haemost, vol. 86, pp. 1583-1584 (2001).
Libourel, et al., “Co-Segregation Of Thrombophilic Disorders In Factor V Leiden Carriers; The Contributions Of Factor VIII, Factor XI, Thrombin Activatable Fibrinolysis Inhibitor And Lipoprotein(a) To The Absolute Risk Of Venous Thromboembolism”, Haematologica, vol. 87, pp. 1068-1073 (2002).
Tsai, et al., “The Gene Encoding Human Plasma Carboxypeptidase B (CPB2) Resides On Chromosome 13”, Genomics, vol. 14, pp. 549-550 (1992).
Zhao, et al., “Identification And Characterization Of Two Thrombin-Activatable Fibrinolysis Inhibitor Isoforms”, Thromb Haemost, vol. 80, pp. 949-955 (1998).
Antovic, et al., “Does Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Contribute To Impairment Of Fibrinolysis In Patients With Preeclampsia And/Or Intrauterine Fetal Growth Retardation?”, Thromb Haemost, vol. 88, pp. 644-647 (2002).
Pascual, et al., “Purification And Properties Of Five Different Forms Of Human Procarboxypeptidases”, Eur. J. Biochem., vol. 179, pp. 609-616 (1989).
Matsumoto, et al., “A Novel Carboxypeptidase B that Processes Native β-amyloid Precursor Protein Is Present In Human Hippocampus”, Eur. J. of Neuroscience, vol. 12, pp. 227-238 (2000).
Zhao, et al., “Mutations In The Substrate Binding Site Of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Alter Its Substrate Specificity”, J. Biol. Chem., vol. 278, pp. 32359-32366 (2003).
Colucci, et al., “Deficiency Of Thrombin Activatable Fibrinolysis Inhibitor In Cirrhosis Is Associated With Increased Plasma Fibrinolysis”, Hepatology, vol. 38 (1), pp. 230-237 (2003).
Yano, et al., “Increased Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels In Normotensive Type 2 Diabetic Patients With Microalbuminuria”, J. Clin. Endocrin & Metabolism, vol. 88(2), pp. 736-741 (2003).
Yano, et al., “Association Between Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels And Activated Protein C In Normotensive Type 2 Diabetic Patients”, Diabetes Care, vol. 25(7), pp. 1245-1246 (2002).
Schneider, et al., “Amino Acid Residues In The P6-P′3 Region Of Thrombin-Activable Fibrinolysis Inhibitor (TAFI) Do Not Determine The Thrombinomodulin Dependence Of TAFI Activation”, J. Biol.Chem., vol. 277(12), pp. 9944-9951 (2002).
Eaton, et al., “Isolation, Molecular Cloning, And Partial Characterization Of A Novel Carboxypeptidase B From Human Plasma”, J. Biol. Chem., vol. 266(32), pp. 21833-21838 (1991).
Koschinsky, et al., “Association Of A Single Nucleotide Polymorphism InCPB2Encoding The Thrombin-Activable Fibrinolysis Inhibitor (TAFI) With Blood Pressure”, Clin. Genet, vol. 60, pp. 345-349 (2001).
Boffa, et al., “Characterization Of The Gene Encoding Human TAFI (Thrombin-Activable Fibrinolysis Inhibitor; Plasma Procarboxypeptidase B)”, Biochem., vol. 38, pp. 6547-6558 (1999).
Vanhoof, et al., “The Gene For Human Carboxypeptidase U (CPU)-A Proposed Novel Regulator Of Plasminogen Activation-Maps To 13q14.11”, Genomics, vol. 38, pp. 454-455 (1996).
NCBI Entrez Accession No. 105544 (gi:105544) Eaton, D.L., et al. , Aug. 26, 1999.
NCBI Entrez Accession No. AAA60042 (gi:189687) Eaton, D.L., et al., Jan. 7, 1995.
NCBI Entrez Accession No. AAA94971 (gi:1253712) Drayna, D.T., et al., Apr. 3, 1996.
NCBI Entrez Accession No. AAB45836 (gi:1831382) Drayna, D.T., et al., Feb. 7, 1997.
NCBI Entrez Accession No. AAE36249 (gi:10059544) Morser, M.J., et al., Sep. 7, 2000.
NCBI Entrez Accession No. AAP36662 (gi:30584819) Kalnine, N., et al., May 13, 2003.
NCBI Entrez Accession No. AAW13792 (gi:56646729) Gan, W., et al., Dec. 15, 2004.
NCBI Entrez Accession No. AAX29427 (gi:60653465) Hines, L., et al., Mar. 29, 2005.
NCBI Entrez Accession No. AAX29428 (gi:60653467) Hines, L., et al., Mar. 29, 2005.
NCBI Entrez Accession No. CAI10905 (gi:55859590) Griffiths, C., May 18, 2005.
NCBI Entrez Accession No. Q96IY4 (gi:62899885) Eaton, D.L., Feb. 7, 2006.
NCBI Entrez Accession No. XP—007121 (gi:11434004) NCBI Annotation Project, Jul. 16, 2001.
NCBI Entrez Accession No. XP—165638 (gi:20547646) NCBI Annotation Project, May 13, 2002.
Antovic, J.P. et al., “Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation”, Thrombosis Research, vol. 106, pp. 59-62 (2002).
Antovic, J.P. et al., “Does thrombin activatable Fibrinolysis inhibitor (TAFI) Contribute to Impairment of Fibrinolysis in Patients with Preeclampsia and/or Intrauterine Fetal Growth Retardation?”, Thromb Haemost, vol. 88, pp. 644-647 (2002).
Antovic, J.P. et al., “Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebra

Affiliated with

Also associated with

Rating

Nucleic acid molecules and polypeptides encoding baboon TAFI does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acid molecules and polypeptides encoding baboon TAFI, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid molecules and polypeptides encoding baboon TAFI will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3609295